These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7624897)

  • 1. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients.
    Bendriss A; Bechtel Y; Paintaud G; Bendriss EK; Joanne C; Bresson-Hadni S; Magnette J; Becker MC; Gillet M; Mantion G
    Ther Drug Monit; 1995 Apr; 17(2):113-9. PubMed ID: 7624897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4.
    Monek O; Paintaud G; Bechtel Y; Miguet JP; Mantion G; Bechtel PR
    Eur J Clin Pharmacol; 1998 Mar; 54(1):47-52. PubMed ID: 9591930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
    Jaruratanasirikul S; Cooper AD; Blaschke TF
    Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
    Kronbach T
    Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
    [No Abstract]   [Full Text] [Related]  

  • 9. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
    Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
    Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB; Boeve TJ; Hande KR
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
    Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
    Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
    Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
    Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.